Issues Form 483 with four procedural observations
Alembic Pharmaceuticals announced that US Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals General Oral Solid Formulation Facility located at Panelav from 9 March 2020 to 13 March 2020. This was a scheduled inspection and at the end of the inspection, the USFDA issued a Form 483 with four procedural observations.None of the observations are related to data integrity or repetitive in nature.
The Company will provide comprehensive corrective action report to address each observation. The Company is committed to maintaining highest quality standards that meet USFDA standards.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app